The price of Teladoc Health Inc (NYSE: TDOC) closed at $14.58 in the last session, up 1.32% from day before closing price of $14.39. In other words, the price has increased by $+0.19 from its previous closing price. On the day, 4086756 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
We take a closer look at TDOC’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.17 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 7.19. For the most recent quarter (mrq), Quick Ratio is recorded 3.39 and its Current Ratio is at 3.46. In the meantime, Its Debt-to-Equity ratio is 0.68 whereas as Long-Term Debt/Eq ratio is at 0.68.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on February 29, 2024, initiated with a Overweight rating and assigned the stock a target price of $22.
On February 26, 2024, Leerink Partners started tracking the stock assigning a Market Perform rating and target price of $17.
DA Davidson Downgraded its Buy to Neutral on January 17, 2024, whereas the target price for the stock was revised from $33 to $22.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 05 ’24 when Turitz Andrew sold 5,647 shares for $14.53 per share. The transaction valued at 82,051 led to the insider holds 33,782 shares of the business.
GOREVIC JASON N sold 53,755 shares of TDOC for $780,308 on Mar 04 ’24. The CHIEF EXECUTIVE OFFICER now owns 653,073 shares after completing the transaction at $14.52 per share. On Mar 04 ’24, another insider, Murthy Mala, who serves as the CHIEF FINANCIAL OFFICER of the company, sold 29,888 shares for $14.52 each. As a result, the insider received 433,854 and left with 71,716 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TDOC now has a Market Capitalization of 2.44B and an Enterprise Value of 2.90B. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.94 while its Price-to-Book (P/B) ratio in mrq is 1.04. Its current Enterprise Value per Revenue stands at 1.12 whereas that against EBITDA is 18.86.
Stock Price History:
Over the past 52 weeks, TDOC has reached a high of $30.41, while it has fallen to a 52-week low of $14.29. The 50-Day Moving Average of the stock is 19.59, while the 200-Day Moving Average is calculated to be 21.05.
Shares Statistics:
According to the various share statistics, TDOC traded on average about 4.83M shares per day over the past 3-months and 9.67M shares per day over the past 10 days. A total of 166.66M shares are outstanding, with a floating share count of 165.38M. Insiders hold about 0.99% of the company’s shares, while institutions hold 77.43% stake in the company. Shares short for TDOC as of Feb 15, 2024 were 20.51M with a Short Ratio of 4.24, compared to 22.98M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 12.30% and a Short% of Float of 13.98%.
Earnings Estimates
The company has 21 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.45 for the current quarter, with a high estimate of -$0.28 and a low estimate of -$0.54, while EPS last year was -$0.42. The consensus estimate for the next quarter is -$0.3, with high estimates of -$0.17 and low estimates of -$0.41.
Analysts are recommending an EPS of between -$0.73 and -$1.38 for the fiscal current year, implying an average EPS of -$1.02. EPS for the following year is -$0.68, with 20 analysts recommending between -$0.15 and -$1.17.
Revenue Estimates
According to 24 analysts, the current quarter’s revenue is expected to be $638.98M. It ranges from a high estimate of $674.19M to a low estimate of $632.57M. As of the current estimate, Teladoc Health Inc’s year-ago sales were $618.31M, an estimated increase of 3.30% from the year-ago figure. For the next quarter, 24 analysts are estimating revenue of $664.41M, an increase of 2.30% less than the figure of $3.30% in the same quarter last year. There is a high estimate of $697.07M for the next quarter, whereas the lowest estimate is $642.6M.
A total of 26 analysts have provided revenue estimates for TDOC’s current fiscal year. The highest revenue estimate was $2.79B, while the lowest revenue estimate was $2.64B, resulting in an average revenue estimate of $2.67B. In the same quarter a year ago, actual revenue was $2.6B, up 2.60% from the average estimate. Based on 25 analysts’ estimates, the company’s revenue will be $2.77B in the next fiscal year. The high estimate is $2.99B and the low estimate is $2.72B. The average revenue growth estimate for next year is up 3.80% from the average revenue estimate for this year.
